Nnyocha nke nọọrọ onwe ya sitere na Germany na-akwado na neuromodulation bimodal nwere ike ibelata akara ngosi tinnitus na ọnọdụ ụlọ ọgwụ n'ezie.
Ụlọ ọrụ ahụike Irish, Neuromod Devices Ltd. (Neuromod), anabatala nchọpụta nke nchọpụta onwe onye mere na German Hearing Center (DHZ) na Hannover Medical School, nke chọpụtara na 85% nke ndị ọrịa tinnitus nwetara mbelata na mgbaàmà tinnitus ha. (dabere na Tinnitus Handicap Inventory score[i] gafee ndị ọrịa 20) mgbe ị na-eji ngwaọrụ ọgwụgwọ Lenire.
Ọmụmụ ihe a gosiri na ọgwụgwọ izu isii ruo 12 na-eji Lenire, ngwaọrụ neuromodulation bimodal mepụtara nke Neuromod nke na-enye mkpali ụda na ọkụ eletrik nke ire, nwere ike nweta nkwalite ahụike dị mma na tinnitus akara nrịanrịa na ọnọdụ ụlọ ọgwụ n'ezie.
Ọ bụ Dr. Thomas Lenarz, Anke Lesinski-Schiedat, na Andreas Buechner sitere na Ngalaba Otolaryngology na Hannover Medical School, Germany.
Ebipụtara nsonaazụ ndị a n'oge na-adịbeghị anya n'akwụkwọ akụkọ sayensị a họọrọ nke ukwuu, Brain Stimulation[ii].
Ihe omuma nke uwa n'ezie kwekọrọ na nsonazụ nke Neuromod's large-scale clinical trial (TENT-A1), nke gụnyere ndị sonyere 326. Nnwale TENT-A1, nsonaazụ ya nke ebipụtara na Ọktoba 2020[iii], gosiri na 86.2% nke ndị sonyere n'ọgwụgwọ ahụ gosipụtara mmụba na mgbaama tinnitus ha mgbe oge izu iri na abụọ jiri Lenire.
Ọmụmụ Hannover gụnyere oge ọgwụgwọ dị mkpirikpi (izu 6-12) wee hụ mmụba pụtara (mbelata) na akara THI nke isi 10.4, nke karịrị ihe dị iche iche pụtara ụlọ ọgwụ nke isi 7. Ihe omuma a n'ezie nke sitere na omumu Hannover kwekọrọ na nyocha nke TENT-A1, nke huru mmelite yiri nke a mgbe izu 6 gasịrị nke ọgwụgwọ wee nweta ngụkọta nke 14.6 isi nkwalite mgbe izu 12 zuru ezu nke ọgwụgwọ. Ọzọkwa, ọnweghị ihe omume ọjọọ metụtara ọgwụgwọ akọpụtara.
Lenire na-arụ ọrụ site n'ibunye obere ọkụ eletrik n'ire, site na akụrụngwa intra-oral a na-akpọ 'Tonguetip', yana ụda a na-akpọ site na ekweisi iji mee mgbanwe ogologo oge ma ọ bụ neuroplasticity na ụbụrụ iji gwọọ tinnitus.
Nnwale ụlọ ọgwụ TENT-A1, nke metụtara ndị sonyere 326 n'ofe Ireland na Germany, gosipụtara arụmọrụ Lenire n'ịkwalite mgbaàmà tinnitus nke onye so na ya. 86.2% nke ndị sonyere na-ahụ maka ọgwụgwọ gosipụtara mmụba na mgbaàmà tinnitus ha mgbe oge ọgwụgwọ izu iri na abụọ gasịrị [iv]. Mgbe ọnwa iri na abụọ na-esochi ọgwụgwọ, 12% nke ndị sonyere na-agbaso usoro ọgwụgwọ akwadola mmelite na mgbaàmà tinnitus ha.
Ọmụmụ TENT-A1 na-anọchite anya otu n'ime nnwale ụlọ ọgwụ kachasị na ogologo na-esote emetụrụla n'ọhịa tinnitus ma bụrụ akụkọ mkpuchi maka akwụkwọ akụkọ sayensị Science Translational Medicine na Ọktọba 2020.
Neuromod bụ ọkachamara na teknụzụ neuromodulation na-adịghị emerụ ahụ ma chepụta ma mepụta Lenire, nke ejirila na-agwọ ndị ọrịa tinnitus kemgbe 2019.
